CEO Christopher Posner stated that the company aims to evaluate various options while implementing a cost-containment and cash conservation plan. There is no guarantee that this process will lead to any agreements or transactions, and further updates will only be provided if the Board approves a specific action or if legally required.

As of March 31, Cara Therapeutics said the company had about $70 million in cash and marketable securities.

Read Also: Inflation Slows More Expected To 3% In June, Heightens Expectations For Rate Cuts: Treasury Yields Tumble

Should I Sell My CARA Stock?

Whether to sell or hold a stock largely depends on an investor's strategy and risk tolerance. Swing traders may sell an outperforming stock to lock in a capital gain, while long-term investors might ride out the turbulence in anticipation of further share price growth.

Similarly, traders willing to minimize losses may sell a stock that falls a certain percentage, while long-term investors may see this as an opportunity to buy more shares at a discounted price.

Investors may also consider market dynamics. The Relative Strength Index can be used to indicate whether a stock is overbought or oversold. Cara Therapeutics stock currently has an RSI of 47.81, indicating neutral conditions.

For analysis tools, charting data and access to exclusive stock news, check out Benzinga PRO. Try it for free.

Read Next:

• Pfizer Advances Once-Daily Weight-Loss Pill As It Catches Up To Tap The Lucrative Market

Image created using artificial intelligence via Midjourney.